Production of Genetically Engineered Biotinylated Interleukin-2 and Its Application in a Rapid Nonradioactive Assay for T-Cell Activation

ABSTRACT The development of reliable assay systems that can measure lymphocyte activation in vitro has been a major goal of immunodiagnostics. Traditionally, tritiated thymidine incorporation has been used to monitor T-cell activation. Other methods include enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot assay, and colorimetric assays. We have established a lymphocyte activation assay that utilizes fluorescein isothiocyanate (FITC)-streptavidin bound to recombinant biotinylated human interleukin-2 (IL-2). Utilizing recombinant DNA technology, a unique monobiotinylated human IL-2 has been created and isolated using the Promega PinPoint vector system. ELISA has been used to demonstrate streptavidin binding and recognition by a human IL-2-specific antibody. IL-2 function has been demonstrated using a murine IL-2-dependent T-cell line, CTLL-2, responsive to human IL-2. Recombinant biotinylated human IL-2 conjugated to streptavidin-FITC or streptavidin-horseradish peroxidase has been used to monitor T-cell activation in the presence of antigen as well as mitogen. The sensitivity and convenience of this method make this lymphocyte activation assay an attractive alternative to tritiated thymidine incorporation as a method for monitoring T-cell activation. In addition, the availability of a recombinant biotinylated human IL-2 will permit the production of a uniform product suitable for diagnostic and clinical application.

[1]  M. Kuroki,et al.  Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. , 2002, Anticancer research.

[2]  Wei Li,et al.  A novel design of targeted endocrine and cytokine therapy for breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Holden,et al.  Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  S. Morrison,et al.  Antibody-cytokine fusion proteins for the therapy of cancer. , 2001, Journal of immunological methods.

[5]  B. Boehm,et al.  Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. , 2000, Journal of immunological methods.

[6]  D. Collins,et al.  T-lymphocyte functionality assessed by analysis of cytokine receptor expression, intracellular cytokine expression, and femtomolar detection of cytokine secretion by quantitative flow cytometry. , 1998, Cytometry.

[7]  P. Simms,et al.  Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation , 1996, Clinical and diagnostic laboratory immunology.

[8]  T. Fujita,et al.  Molecular cloning and characterization of murine IL-12 genes. , 1996, Journal of immunology.

[9]  N. Petrovsky,et al.  Cytokine-based human whole blood assay for the detection of antigen-reactive T cells. , 1995, Journal of immunological methods.

[10]  R. Foà,et al.  The IL-2 receptor complex: expression and function on normal and leukemic B cells. , 1995, Leukemia.

[11]  H. Rozemuller,et al.  Biotinylation of interleukin-2 (IL-2) for flow cytometric analysis of IL-2 receptor expression. Comparison of different methods. , 1995, Journal of immunological methods.

[12]  C. Orosz,et al.  Nonradioactive alternative to clinical mixed lymphocyte reaction. , 1995, Human immunology.

[13]  J. Fisher,et al.  Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. , 1992, Journal of immunology.

[14]  H. Wang,et al.  A colorimetric method for detection of specific ligand binding. , 1992, Analytical biochemistry.

[15]  P. Familletti,et al.  Cloning and expression of murine IL-12. , 1992, Journal of immunology.

[16]  David Peters,et al.  Binding and internalization of biotinylated interleukin-2 in human lymphocytes. , 1990, Blood.

[17]  J. Cronan.  Biotination of proteins in vivo. A post-translational modification to label, purify, and study proteins. , 1990, The Journal of biological chemistry.

[18]  Y. Takahara,et al.  Biotinylation of human interleukin-2 for flow cytometry analysis of interleukin-2 receptors. , 1989, Journal of immunological methods.

[19]  B. Ryffel,et al.  Biotinylated recombinant interleukin-2. A tool for research on the interleukin-2 receptor. , 1988, Journal of immunological methods.

[20]  H. Wood,et al.  Evolutionary conservation among biotin enzymes. , 1988, The Journal of biological chemistry.

[21]  S. Mudzinski,et al.  A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen. , 2003, Biomolecular engineering.

[22]  R. Reisfeld,et al.  Targeted cytokines for cancer immunotherapy , 2000, Immunologic research.

[23]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[24]  N. Rose,et al.  Use of a simple light absorbance assay to measure lymphocyte proliferation. , 1998, Journal of immunoassay.

[25]  M. Ratain,et al.  Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. , 1997, European journal of cancer.

[26]  Ewa M. Bielihska,et al.  COMPARISON OF DIFFERENT METHODS , 1994 .